Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 16/20 | 0.52 |
| ▸ | FNTB | P49356 | 16/20 | 0.52 |
| ▸ | PGGT1B | P53609 | 5/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13501472 | 0.95 | FNTA (0.55) | FNTAFNTBPGGT1BCYP3A4 | |
| SCHEMBL13501494 | 0.95 | FNTA (0.55) | FNTAFNTBPGGT1BCYP3A4 | |
| SCHEMBL13899734 | 0.88 | FNTA (0.50) | FNTAFNTBPGGT1BCYP3A4ALDH1A1 | |
| SCHEMBL3554724 | 0.84 | FNTA (0.50) | FNTAFNTBPGGT1B | |
| SCHEMBL13899736 | 0.83 | FNTA (0.53) | FNTAFNTBPGGT1BCYP3A4ALDH1A1 | |
| SCHEMBL13501493 | 0.82 | FNTA (0.40) | FNTAFNTBPGGT1BCYP3A4ALDH1A1 | |
| SCHEMBL13501498 | 0.82 | FNTA (0.45) | FNTAFNTBPGGT1B | |
| SCHEMBL3548298 | 0.82 | FNTA (0.45) | FNTAFNTBPGGT1B | |
| SCHEMBL3978049 | 0.81 | FNTA (0.43) | FNTAFNTBPGGT1BALDH1A1SMN1; SMN2 | |
| SCHEMBL3547921 | 0.80 | FNTA (0.58) | FNTAFNTBPGGT1BCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655654-B2 | Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-02 | — | — | US | disclosed |
| US-7655654-B2 | Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-02 | — | — | US | disclosed |
| US-7655654-B2 | Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-02 | — | — | US | disclosed |
| US-7511138-B2 | Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles | JANSSEN PHARMACEUTICA NV (BE) | 2009-03-31 | — | — | US | disclosed |
| US-7511138-B2 | Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles | JANSSEN PHARMACEUTICA NV (BE) | 2009-03-31 | — | — | US | disclosed |
| US-20080027086-A1 | FARNESYL TRANSFERASE INHIBITING TRICYCLIC QUINAZOLINE DERIVATIVES SUBSTITUTED WITH CARBON-LINKED IMIDAZOLES OR TRIAZOLES | ANGIBAUD PATRICK R | 2008-01-31 | — | — | US | disclosed |
| US-20080027086-A1 | FARNESYL TRANSFERASE INHIBITING TRICYCLIC QUINAZOLINE DERIVATIVES SUBSTITUTED WITH CARBON-LINKED IMIDAZOLES OR TRIAZOLES | ANGIBAUD PATRICK R | 2008-01-31 | — | — | US | disclosed |
| US-20080027086-A1 | FARNESYL TRANSFERASE INHIBITING TRICYCLIC QUINAZOLINE DERIVATIVES SUBSTITUTED WITH CARBON-LINKED IMIDAZOLES OR TRIAZOLES | ANGIBAUD PATRICK R | 2008-01-31 | — | — | US | disclosed |
| EP-1497295-B1 | FARNESYL TRANSFERASE INHIBITING TRICYCLIC QUINAZOLINE DERIVATIVES SUBSTITUTED WITH CARBON-LINKED IMIDAZOLES OR TRIAZOLES | JANSSEN PHARMACEUTICA NV (BE) | 2006-08-16 | — | — | EP | disclosed |
| US-20050148609-A1 | Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles of triazoles | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148609-A1 | Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles of triazoles | FNTA, FNTB, HCCS | FNTA 1/4885FNTB 2/4885PGGT1B 32/4885 |
| US-20080027086-A1 | FARNESYL TRANSFERASE INHIBITING TRICYCLIC QUINAZOLINE DERIVATIVES SUBSTITUTED WITH CARBON-LINKED IMIDAZOLES OR TRIAZOLES | FNTA, FNTB, CYP7A1 | FNTA 1/4885FNTB 2/4885PGGT1B 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.